{"id":2428,"date":"2026-05-07T21:00:00","date_gmt":"2026-05-07T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=a4017b99a66993bf385b25f1b0d84a01"},"modified":"2026-05-07T21:00:00","modified_gmt":"2026-05-07T19:00:00","slug":"number-of-shares-and-voting-rights-of-adocia-as-of-april-30-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=2428","title":{"rendered":"Number of Shares and Voting Rights of ADOCIA as of April 30, 2026"},"content":{"rendered":"

LYON, France--(BUSINESS WIRE)--#BIOTECH<\/a>--Regulatory News:<\/p><\/a><\/a>

\nPursuant to the provisions of article L. 233-8 II of the French \u201cCode de Commerce\u201d and article 223-16 of the General Regulation of the French stock-market authorities (Autorit\u00e9 des March\u00e9s Financiers<\/i>, or \u201cAMF\u201d), ADOCIA SA (Paris:ADOC), a French soci\u00e9t\u00e9 anonyme<\/i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 \u2013 ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of April 30, 2026.<\/p>\n\n\n

\nMonth<\/p><\/td>

\nDate<\/p><\/td>

\nTotal number of\noutstanding shares<\/p><\/td>

\nTotal number of\ntheoretical voting rights (1)<\/p><\/td>

\nTotal number of\nexercisable voting rights (2)<\/p><\/td><\/tr>\n

\nApril<\/p><\/td>

\n04\/30\/2026<\/p><\/td>

\n19,608,056<\/p><\/td>

\n21,019,586<\/p><\/td>

\n20,981,989<\/p><\/td><\/tr>\n<\/table>

\n(1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.<\/i><\/p>

\n(2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement.<\/i> It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007.<\/i><\/p>

\nAbout Adocia<\/b><\/p>

\nAdocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.<\/p>

\nThe Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone\u00ae for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral\u00ae, an oral peptide delivery technology; 3) AdoShell\u00ae, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLongTM<\/sup>, a long-acting peptide platform.<\/p>

\nAdocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext\u2122 Paris (Euronext: ADOC; ISIN: FR0011184241).<\/p> Contacts<\/b>

\nAdocia<\/b>Olivier Soula<\/b>CEO\ncontactinvestisseurs@adocia.com<\/a>+33 (0)4 72 610 610\nwww.adocia.com<\/a><\/p>

\nMaarc<\/b>Adocia Press & Investor Relations<\/b>Bruno Arabian\nYasmine Duval\nThomas Rolnik\nadocia-actionnaires@maarc.fr<\/a>+ 33 (0)6 87 88 47 26<\/p>","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–#BIOTECH–Regulatory News:
\nPursuant to the provisions of article L. 233-8 II of the French \u201cCode de Commerce\u201d and article 223-16 of the General Regulation of the French stock-market authorities (Autorit\u00e9 des March\u00e9s Finan…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2428","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2428"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2428\/revisions"}],"predecessor-version":[{"id":2429,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2428\/revisions\/2429"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}